Use of Ketamine for Conscious Sedation in Flexible Bronchoscopy
Status:
Completed
Trial end date:
2023-10-30
Target enrollment:
Participant gender:
Summary
In this study, the investigators plan to conduct a single blinded randomized controlled trial
in the Pulmonary Service to demonstrate the efficacy of ketamine and its utility in moderate
sedation. Patients presenting for bronchoscopy who meet inclusion criteria will be
approached, and if amenable, will be consented and enrolled. Patients will be randomized to
receive either 1 mg of midazolam and ketamine 0.25 to 0.5 mg/kg loading dose with subsequent
doses of 10-20 mg IV or standard fentanyl and midazolam in 25mcg and 1mg increments
respectively for moderate sedation during their procedure. The primary outcome will be
patient satisfaction, which will be measured a using patient clinical satisfaction form. A
number of secondary outcomes will include the following: (1) provider satisfaction (2) the
time from sedation administration to procedure start (when the scope is inserted), (3) the
time from sedation to scope removal from the trachea (4) the time from sedation to discharge
(defined as the time from the end of the procedure until the patient meets discharge criteria
from the recovery area), (5) total dose of medications given (including midazolam, fentanyl,
and ketamine), (6) adverse events, (7) vital signs, (8) and the need for additional
medications, in particular reversal agents.